Trevena Reports End of Phase 2 Meeting, Offers Outline for Phase 3 Program for Oliceridine
May 02, 2016 at 16:08 PM EDT
Trevena, Inc. (NASDAQ: TRVN), a clinical stage biopharmaceutical company focused on the discovery and development of biased ligands ...